In light of these issues, we performed a more comprehensive systematic review and meta-analysis of the currently available evidences, aiming to determine whether first-line treatment with upfront brain RT plus EGFR-TKIs was superior to EGFR-TKIs alone in patients with EGFR-mutated NSCLC with newly diagnosed BMs, and to explore the advantageous groups of the combination therapy by subgroup analyses. This evidence concerns the gene EGFR and non-small cell lung carcinoma.